ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine

BACKGROUND: We aimed to investigate the impact of RRM1 and ERCC1 expression on response to cisplatin and/or gemcitabine chemotherapy in patients with lung, ovarian or pancreatic cancer. MATERIAL AND METHODS: Patients with lung, ovarian or pancreatic cancer, who used cisplatin and/or gemcitabine ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulker, Mehmet, Duman, Berna Bozkurt, Sahin, Berksoy, Gumurdulu, Derya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2015
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631284/
https://www.ncbi.nlm.nih.gov/pubmed/26557761
http://dx.doi.org/10.5114/wo.2015.52656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631284/
https://www.ncbi.nlm.nih.gov/pubmed/26557761
http://dx.doi.org/10.5114/wo.2015.52656

Ejemplares similares